Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Opeyemi A Olabisi

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Kidney International|November 22, 2024
Has APOL1 kidney disease treatment been hiding in plain sight?Opeyemi A Olabisi
Seminars in Nephrology|November 8, 2017
APOL1 Nephrotoxicity: What Does Ion Transport Have to Do With It?Opeyemi A Olabisi, John F Heneghan
Kidney International|June 22, 2021
APOL1-associated kidney disease in northern Nigerians with treated HIV infectionOpeyemi A Olabisi, Barry I Freedman
Methods in Molecular Biology (Clifton, N.J.)|August 27, 2011
Assay for protein modification by poly-ADP-ribose in vitroOpeyemi A Olabisi, Chi-Wing Chow
Progress in Neuro-Psychopharmacology & Biological Psychiatry|April 20, 2004
Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studiesPatricia A Broderick, Opeyemi A Olabisi, David N Rahni, et al.
Journal of the American Society of Nephrology : JASN|July 18, 2020
Kidney Disease-Associated <i>APOL1</i> Variants Have Dose-Dependent, Dominant Toxic Gain-of-FunctionSomenath Datta, Rama Kataria, Jia-Yue Zhang, et al.
Kidney International Reports|September 18, 2024
Design and Rationale of the Phase 2 Baricitinib Study in Apolipoprotein L1-Mediated Kidney Disease (JUSTICE)Opeyemi A Olabisi, Nadine J Barrett, Anika Lucas, et al.
JCI Insight|April 26, 2022
JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoidsSarah E Nystrom, Guojie Li, Somenath Datta, et al.
Kidney International Reports|September 18, 2024
APOL1 High-Risk Genotype is Not Associated With New or Worsening of Proteinuria or Kidney Function Decline Following COVID-19 VaccinationSarah E Nystrom, Karen L Soldano, Micki Rockett, et al.
Journal of the American Society of Nephrology : JASN|March 3, 2026
Hybrid Community-EHR Approaches to APOL1 Kidney Disease Screening and Clinical Trials among Black IndividualsNadine Barrett, Joab O Odera, Kenisha Bethea, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Kidney International|November 22, 2024
Has APOL1 kidney disease treatment been hiding in plain sight?Opeyemi A Olabisi
Seminars in Nephrology|November 8, 2017
APOL1 Nephrotoxicity: What Does Ion Transport Have to Do With It?Opeyemi A Olabisi, John F Heneghan
Kidney International|June 22, 2021
APOL1-associated kidney disease in northern Nigerians with treated HIV infectionOpeyemi A Olabisi, Barry I Freedman
Methods in Molecular Biology (Clifton, N.J.)|August 27, 2011
Assay for protein modification by poly-ADP-ribose in vitroOpeyemi A Olabisi, Chi-Wing Chow
Progress in Neuro-Psychopharmacology & Biological Psychiatry|April 20, 2004
Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studiesPatricia A Broderick, Opeyemi A Olabisi, David N Rahni, et al.
Journal of the American Society of Nephrology : JASN|July 18, 2020
Kidney Disease-Associated <i>APOL1</i> Variants Have Dose-Dependent, Dominant Toxic Gain-of-FunctionSomenath Datta, Rama Kataria, Jia-Yue Zhang, et al.
Kidney International Reports|September 18, 2024
Design and Rationale of the Phase 2 Baricitinib Study in Apolipoprotein L1-Mediated Kidney Disease (JUSTICE)Opeyemi A Olabisi, Nadine J Barrett, Anika Lucas, et al.
JCI Insight|April 26, 2022
JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoidsSarah E Nystrom, Guojie Li, Somenath Datta, et al.
Kidney International Reports|September 18, 2024
APOL1 High-Risk Genotype is Not Associated With New or Worsening of Proteinuria or Kidney Function Decline Following COVID-19 VaccinationSarah E Nystrom, Karen L Soldano, Micki Rockett, et al.
Journal of the American Society of Nephrology : JASN|March 3, 2026
Hybrid Community-EHR Approaches to APOL1 Kidney Disease Screening and Clinical Trials among Black IndividualsNadine Barrett, Joab O Odera, Kenisha Bethea, et al.
Pageof 2